These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11962679)

  • 1. Circadian chemotherapy for gynecological and genitourinary cancers.
    Kobayashi M; Wood PA; Hrushesky WJ
    Chronobiol Int; 2002 Jan; 19(1):237-51. PubMed ID: 11962679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronopharmacology and chronotherapy of cancers].
    Lévi F
    Pathol Biol (Paris); 1996 Sep; 44(7):631-44. PubMed ID: 8977920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer chronotherapy: a drug delivery challenge.
    Hrushesky WJ
    Prog Clin Biol Res; 1990; 341A():1-10. PubMed ID: 2145583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
    Hrushesky WJ; von Roemeling R; Lanning RM; Rabatin JT
    J Clin Oncol; 1990 Sep; 8(9):1504-13. PubMed ID: 2144018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
    Reese DM; Corry M; Small EJ
    Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
    von Roemeling R; Hrushesky WJ
    J Clin Oncol; 1989 Nov; 7(11):1710-9. PubMed ID: 2530318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer.
    Rajagopalan K; Peereboom D; Budd GT; Olencki T; Murthy S; Elson P; McLain D; Bukowski R
    Invest New Drugs; 1998-1999; 16(3):255-8. PubMed ID: 10360605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chrono-chemotherapy and dose intensity].
    Lévi F
    Bull Cancer; 1995; 82 Suppl 1():29s-36s. PubMed ID: 7626851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian-based infusional FUDR therapy.
    Lanning RM; von Roemeling R; Hrushesky WJ
    Oncol Nurs Forum; 1990; 17(1):49-56. PubMed ID: 2137216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
    Conroy T; Geoffrois L; Guillemin F; Luporsi E; Krakowski I; Spaëth D; Frasie V; Volff D
    Cancer; 1993 Oct; 72(7):2190-7. PubMed ID: 8374877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
    Garufi C; Lévi F; Giunta S; Aschelter A; Pace R; Nisticò C; Terzoli E
    J Infus Chemother; 1995; 5(3 Suppl 1):134-7. PubMed ID: 8528973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma.
    Damascelli B; Marchianò A; Frigerio LF; Salvetti M; Spreafico C; Garbagnati F; Zanoni F; Radice F
    Cancer; 1991 Sep; 68(5):995-8. PubMed ID: 1833043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
    Hrushesky WJ; Von Roemeling R; Fraley EE; Rabatin JT
    Semin Surg Oncol; 1988; 4(2):110-5. PubMed ID: 2969133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
    Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
    J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
    Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
    J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
    Bjarnason GA; Doyle N; Sone M; Beattie K; Elia J; Owens B
    J Infus Chemother; 1995; 5(2):82-8. PubMed ID: 8521240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
    Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD
    Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms.
    Ostrow S; Egorin MJ; Hahn D; Markus S; Leroy A; Chang P; Klein M; Bachur NR; Wiernik PH
    Cancer; 1980 Oct; 46(8):1715-21. PubMed ID: 7191768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of urogenital cancers].
    Matsumura Y; Tsushima T
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):181-9. PubMed ID: 2041265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.